Pancreatic cancer has long confounded medicine by constructing within itself a biological fortress that repels the immune therapies that have reshaped oncology elsewhere. Researchers at the University of Chicago have now turned that fortress's own conditions against it, engineering a common gut bacterium to thrive precisely where tumors are most hostile and deliver immune-awakening therapy from within. The work, published in Science Advances, represents not merely a new drug but a new philosophy of delivery — using living organisms as targeted messengers in the body's most defended territories
Engineered probiotic bacteria show promise against hard-to-treat pancreatic cancer
Microscopic factories producing immune therapy on-site
Mark
Why is pancreatic cancer so much harder to treat than other cancers?
Mimi
The tumor itself creates a hostile environment for immune cells. It's not just that the cancer grows fast—it actively suppresses the immune response, making standard immunotherapies less effective.
Mark
And the bacteria solve this by doing what, exactly?
Mimi
They act as delivery vehicles. They travel through the bloodstream, but only become active inside the tumor where oxygen is scarce. Once there, they produce an immune-stimulating molecule that wakes up the body's cancer-fighting T cells.
Mark
Why use a probiotic? Why not just inject the immune molecule directly?
Mimi
Because injecting IL-2 directly causes severe side effects throughout the body. By concentrating it only inside the tumor, you get the therapeutic benefit without harming healthy tissue.
Mark
Is this ready for patients?
Mimi
Not yet. The work has only been done in animal models. Researchers need to test it in humans, figure out if it can be given orally, and understand how long the immune response lasts.
Mark
What makes you think it will work in people?
Mimi
The biology is sound, and the combination results in animals were impressive. But cancer research is full of promising animal studies that don't translate. That's why the next phase matters so much.
El Pulso
- Pancreatic tumors actively suppress immune responses, creating a 'cold' microenvironment that has made the cancer one of medicine's most stubborn adversaries.
- Scientists engineered a probiotic bacterium — the kind found in yogurt — to seek out low-oxygen tumor environments and produce immune-stimulating molecules directly on-site, bypassing the systemic toxicity that has plagued traditional IL-2 therapy.
- In animal models, the therapy not only slowed tumor growth on its own but compounded dramatically when paired with chemotherapy, radiation, or checkpoint immunotherapy — a combination effect researchers called among the study's most significant findings.
- The path to human trials remains long, with unanswered questions about oral delivery, immune response durability, and safety profiles, while the team eyes potential synergy with emerging KRAS inhibitor drugs.
Pancreatic cancer has long confounded medicine by constructing within itself a biological fortress that repels the immune therapies that have reshaped oncology elsewhere. Researchers at the University of Chicago have now turned that fortress's own conditions against it, engineering a common gut bacterium to thrive precisely where tumors are most hostile and deliver immune-awakening therapy from within. The work, published in Science Advances, represents not merely a new drug but a new philosophy of delivery — using living organisms as targeted messengers in the body's most defended territories.
Pancreatic cancer has long resisted the immunotherapy revolution, because its tumors build what researchers call a cold microenvironment — a landscape so hostile that immune cells cannot mount an effective attack. Scientists at the University of Chicago have responded with a therapy that repurposes biology itself: an engineered probiotic bacterium called BifidoSumIL-2, designed to infiltrate tumors and awaken the immune system from within.
The vehicle is Bifidobacterium longum, a bacterium already familiar to the human gut. The researchers loaded it with a modified version of interleukin-2 — a potent T-cell activator — engineered to target cancer-fighting immune cells while avoiding the regulatory cells that can actually suppress an antitumor response. The bacterium's own biology does much of the targeting work: it thrives in the low-oxygen depths of solid tumors while being naturally cleared from healthy, oxygen-rich tissue. Injected systemically, it becomes active only where it is needed, functioning as a microscopic drug factory inside the tumor itself.
The engineering was not simple. Assistant professor Mark Mimee noted that Bifidobacterium is slow-growing, anaerobic, and far harder to modify genetically than standard laboratory organisms — much of the research effort went into making reliable manipulation possible at all. The results in animal models, however, were striking: selective tumor accumulation, activated immune responses, and slowed growth. When combined with chemotherapy, radiation, or anti-PD-L1 immunotherapy, the effects compounded, with tumors shrinking further and survival improving beyond what any single treatment achieved alone.
Human trials have not yet begun, and critical questions remain — whether oral delivery is feasible, how durable the immune response proves, and what long-term safety looks like. The team is also exploring combinations with KRAS inhibitors, a newer class of pancreatic cancer drugs. The work belongs to a growing field sometimes called 'bugs as drugs,' in which engineered probiotics offer a fundamentally different strategy for reaching hard-to-treat tumors. For patients facing one of oncology's steepest mountains, this engineered bacterium suggests a new way to begin the climb.
Pancreatic cancer has long resisted the immunotherapies that have transformed treatment for other malignancies. The reason is biological: tumors of the pancreas construct what researchers call a cold microenvironment, a hostile landscape where immune cells struggle to mount an effective attack. Now scientists at the University of Chicago have engineered a solution that sounds almost like science fiction—a modified probiotic bacterium designed to infiltrate tumors and awaken the body's own defenses from within.
The therapy is called BifidoSumIL-2, and it works by repurposing a bacterium that already lives peacefully in the human gut. Bifidobacterium longum, a common probiotic found in yogurt and other fermented foods, becomes a delivery vehicle for a specially engineered immune molecule. The researchers took interleukin-2, or IL-2, a powerful T-cell activator, and modified it into a version called SumIL-2 that targets cancer-fighting cells while avoiding the regulatory T cells that can actually suppress an antitumor response. Traditional IL-2 therapy causes severe side effects; this engineered version concentrates its action precisely where it's needed.
The elegance of the approach lies in the bacterium's own biology. Bifidobacterium thrives in low-oxygen environments—the kind found deep inside solid tumors. Healthy tissues, by contrast, are oxygen-rich and inhospitable to the organism. When injected systemically, the bacteria are naturally cleared from normal tissue but become active only within the tumor itself, functioning as microscopic factories that produce the immune therapy on-site. Mark Mimee, an assistant professor of microbiology at the university, acknowledged the engineering challenge: the organism is slow-growing, anaerobic, and far more difficult to manipulate genetically than laboratory workhorses like E. coli. Much of the research effort went simply into figuring out how to reliably modify it at all.
In animal models, the results were striking. BifidoSumIL-2 accumulated selectively in pancreatic tumors, activated immune responses, and slowed tumor growth. More importantly, when combined with existing cancer treatments—chemotherapy, radiation, or anti-PD-L1 immunotherapy—the effects compounded. Tumors shrank further and survival improved compared to any single treatment alone. Ralph Weichselbaum, chair of radiation and cellular oncology, called this combination potential one of the study's most significant findings. The work, published in Science Advances, drew on expertise spanning microbiology, synthetic biology, oncology, and immunology—a genuinely interdisciplinary effort required to bring together understanding of bacteria, tumors, and immune function.
The path from animal models to human patients remains substantial. Researchers have not yet tested BifidoSumIL-2 in people, and critical questions remain unanswered: Can the therapy be delivered orally instead of by injection? How durable is the immune response? What are the long-term safety profiles and potential off-target effects? The team is also exploring whether this bacterial delivery strategy could work alongside newer pancreatic cancer drugs, including KRAS inhibitors. The study represents a growing field sometimes called "bugs as drugs," in which engineered probiotics offer a fundamentally different way to get powerful therapies into hard-to-treat tumors while sparing the rest of the body from collateral damage. For pancreatic cancer patients, the mountain Weichselbaum described—an unmet medical need of profound proportions—remains steep. But this engineered bacterium suggests a new path upward.
Citas Notables
Pancreatic cancer has been a major unmet medical need, and this represents a new strategy to address it.— Ralph Weichselbaum, MD, University of Chicago
The combination potential is one of the study's most important findings—BifidoSumIL-2 works not only by itself but also with radiotherapy, chemotherapy, and immunotherapy.— Ralph Weichselbaum, MD
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine